BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32227747)

  • 1. Case Report: Traumatic Incomplete Fracture of an Implanon NXT® Contraceptive Implant.
    Howett R; Gertz AM; Kgaswanyane T; Petro G; Morroni C
    Afr J Reprod Health; 2019 Dec; 23(4):124-128. PubMed ID: 32227747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reasons for requesting removal of the hormonal implant, Implanon NXT, at an urban reproductive health clinic in KwaZulu-Natal, South Africa.
    Beesham I; Smit J; Beksinska M; Panday M; Makatini V; Evans S
    S Afr Med J; 2019 Sep; 109(10):750-755. PubMed ID: 31635572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subdermal contraceptive implants.
    Peralta O; Diaz S; Croxatto H
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Women's contraceptive choice following the use of Implanon NXT: Findings from a study in Durban, South Africa.
    Beesham I; Smit J; Bosman SL; Milford C; Panday M; Beksinska M
    Afr J Reprod Health; 2021 Feb; 25(1):41-48. PubMed ID: 34077109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migration of etonogestrel subcutaneous contraceptive implants: systematic review and recommendations for practice.
    Guilbert É; Arguin H; Bélanger M
    Eur J Contracept Reprod Health Care; 2024 Jun; 29(3):115-130. PubMed ID: 38712717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravascular migration of a contraceptive implant].
    de Vries SM; van der Linden PJQ; Huisman MA
    Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropathy associated with etonogestrel implant insertion.
    Brown M; Britton J
    Contraception; 2012 Nov; 86(5):591-3. PubMed ID: 22770789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etonogestrel implant (Implanon) for contraception.
    Drug Ther Bull; 2001 Aug; 39(8):57-9. PubMed ID: 11526801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy.
    Power J; French R; Cowan F
    Cochrane Database Syst Rev; 2007 Jul; 2007(3):CD001326. PubMed ID: 17636668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of a subdermal contraceptive implant (Implanon NXT) that migrated to the axilla by C-arm guidance: A case report and review of the literature.
    Park JU; Bae HS; Lee SM; Bae J; Park JW
    Medicine (Baltimore); 2017 Dec; 96(48):e8627. PubMed ID: 29310336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reports of Two Broken Nexplanon® Rods.
    Campodonico J; Wolfrey J; Buchanan J
    J Am Board Fam Med; 2019; 32(2):269-271. PubMed ID: 30850464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of patients' challenges and barriers related to usage of Implanon®: scoping review protocol.
    Prosad S; Mashamba-Thompson TP; Ojewole E
    Syst Rev; 2018 Oct; 7(1):157. PubMed ID: 30309380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insertion and removal of Implanon: practical considerations.
    Mascarenhas L
    Eur J Contracept Reprod Health Care; 2000 Sep; 5 Suppl 2():29-34. PubMed ID: 11246605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Implanon insertion and removal.
    Levine JP; Sinofsky FE; Christ MF;
    Contraception; 2008 Nov; 78(5):409-17. PubMed ID: 18929739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of Implanon on lipid metabolism in comparison with Norplant.
    Suherman SK; Affandi B; Korver T
    Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
    Varney SJ; Guest JF
    Pharmacoeconomics; 2004; 22(17):1141-51. PubMed ID: 15612832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and early removals of Implanon NXT in South Africa: Perceptions and attitudes of healthcare workers.
    Adeagbo O; Mullick S; Pillay D; Chersich M; Morroni C; Naidoo N; Pleaner M; Rees H
    S Afr Med J; 2017 Oct; 107(10):822-826. PubMed ID: 29397681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difficult removal of subdermal contraceptive implants: a multidisciplinary approach involving a peripheral nerve expert.
    Odom EB; Eisenberg DL; Fox IK
    Contraception; 2017 Aug; 96(2):89-95. PubMed ID: 28583591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' perspectives about why they have their contraceptive Implanon NXT device removed early.
    Flore M; Chen XL; Bonney A; Mullan J; Dijkmans-Hadley B; Hodgkins A; Evans G; Frew H; Lloyd G
    Aust Fam Physician; 2016 Oct; 45(10):740-744. PubMed ID: 27695725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.